Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In this randomized, double-blind trial, researchers studied the effects of canakinumab on 10,061 patients who had previously experienced a myocardial infarction and had a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial involved comparing different doses of canakinumab - 50 mg, 150 mg, and 300 mg - administered subcutaneously every three months, against a placebo.
Primary outcome measures:
Nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death
Conclusion:
Applying anti-inflammatory therapy that targets the interleukin-1 beta [innate immunity](brain:/…